Singapore’s MerLion Starts Phase II European Finafloxacin Trials
This article was originally published in PharmAsia News
Executive Summary
MerLion will enroll as many as 258 patients across centers in Germany and Poland for patients requiring hospitalization for urinary tract infections and pyelonephritis, positive signs for a drug in-licensed by Alcon for North America.
You may also be interested in...
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.